Curaleaf (CURLF) Stock Price, News & Analysis

Company Overview

Curaleaf Holdings, Inc. is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates. The company also offers proprietary CBD wellness products designed to address pain relief, stress management and sleep support. Curaleaf’s dispensaries provide personalized consultation services, allowing both medical patients and adult-use consumers to select products best suited to their needs. In addition, Curaleaf supplies wholesale products to other licensed retailers in states where it holds cultivation and processing licenses.

Founded in 2010, Curaleaf has expanded through strategic acquisitions, including the 2019 purchase of Grassroots Cannabis and the 2020 acquisition of Select, a premium U.S. cannabis oil brand. These transactions have broadened the company’s geographic footprint and product capabilities. Under the leadership of CEO Matt Darin, Curaleaf continues to pursue disciplined growth, regulatory compliance and innovation in cannabinoid research to support its long-term vision of becoming the most trusted brand in global cannabis.

Key Stats

• Today's Range: $3.22 to $3.47
• 50-Day Range: $1.89 to $3.99
• 52-Week Range: $0.72 to $5.05
• Volume: 5.78 million shs
• Average Volume: 1.16 million shs
• Market Capitalization: $2.32 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

Curaleaf Stock Analysis - MarketRank™

Curaleaf scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Curaleaf has received a consensus rating of Strong Buy. The company's average rating score is 3.75, and is based on 3 strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Curaleaf has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Curaleaf are expected to decrease in the coming year, from ($0.10) to ($0.21) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Curaleaf is -25.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Curaleaf is -25.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Curaleaf has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.95% of the float of Curaleaf has been sold short.

Short Interest Ratio / Days to Cover

Curaleaf has a short interest ratio ("days to cover") of 1.51, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Curaleaf has recently decreased by 17.14%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Curaleaf does not currently pay a dividend.

Dividend Growth

Curaleaf does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.59

News Sentiment

Curaleaf has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Curaleaf this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for CURLF on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

21 people have added Curaleaf to their MarketBeat watchlist in the last 30 days. This is an increase of 110% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Curaleaf insiders have not sold or bought any company stock.

Percentage Held by Institutions

0.03% of the stock of Curaleaf is held by institutions.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CURLF
• CIK: 1756770
• Web: www.curaleaf.com
• Phone: 781-451-0351
• Fax: N/A
• Employees: 5,554
• Year Founded: 2009

Profitability

• EPS (Trailing Twelve Months): ($0.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$231.07 million
• Net Margins: -7.76%
• Pretax Margin: -7.00%
• Return on Equity: -8.11%
• Return on Assets: -2.36%

Debt

• Debt-to-Equity Ratio: 1.05
• Current Ratio: 1.56
• Quick Ratio: 0.74

Sales & Book Value

• Annual Sales: $1.27 billion
• Price / Sales: 1.83
• Cash Flow: $0.05 per share
• Price / Cash Flow: 60.58
• Book Value: $1.18 per share
• Price / Book: 2.81

Miscellaneous

• Outstanding Shares: 698,200,000
• Free Float: N/A
• Market Cap: $2.32 billion
• Optionable: Not Optionable
• Beta: 1.58